OFFICE OF THE SECRETARY OF STATE
TOBIAS READ
SECRETARY OF STATE

MICHAEL KAPLAN
DEPUTY SECRETARY OF STATE

ARCHIVES DIVISION
STEPHANIE CLARK
DIRECTOR

800 SUMMER STREET NE
SALEM, OR 97310
503-373-0701

PERMANENT ADMINISTRATIVE ORDER

BP 6-2026

CHAPTER 855
BOARD OF PHARMACY

FILED: 06/17/2026 9:46 AM
ARCHIVES DIVISION SECRETARY OF STATE & LEGISLATIVE COUNSEL

FILING CAPTION: Updates incorporated standards adopted by reference

EFFECTIVE DATE: 06/17/2026

AGENCY APPROVED DATE: 06/11/2026

CONTACT:
Rachel Melvin
971-673-0001
pharmacy.rulemaking@bop.oregon.gov
800 NE Oregon St., Suite 150
Portland, OR 97232

Filed By:
Rachel Melvin
Rules Coordinator

RULES:
855-041-1046, 855-041-1092, 855-041-1145, 855-041-7050, 855-080-0020, 855-080-0021, 855-080-0022, 855-080-0023, 855-080-0024, 855-080-0026, 855-080-0028, 855-080-0031, 855-080-0065, 855-080-0070, 855-080-0075, 855-080-0085, 855-115-0130, 855-120-0005, 855-135-0001, 855-139-0145, 855-139-0350, 855-139-0460, 855-141-0350

AMEND: 855-041-1046

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the United States Code (USC) and Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-041-1046
Secure and Responsible Drug Disposal ¶

(1) A pharmacy that operates a drug take back collection program or that participates in a drug take-back program under ORS 459A.200 to ORS 459A.266 as an authorized collector must be registered with the DEA as an authorized collector to collect controlled and non-controlled drugs for destruction.¶

(2) A pharmacy that operates as a Drug Enforcement Agency (DEA) authorized collector must notify the board within 30 days of initiating or terminating the program and must establish and enforce policies and procedures, including but not limited to:¶
(a) Provision of a secure location of the collection receptacle inside the retail drug outlet, which is accessible to the public, within view of the pharmacy counter and must not be located behind the pharmacy counter; and¶
(b) Provision of adequate security measures, including proper installation and maintenance of the collection receptacle, tracking of liners, documentation, and key accountability; and¶
(c) Personnel training and accountability.¶
(3) A pharmacy must inform consumers to directly deposit drugs into the collection receptacle. Pharmacy personnel must not count, sort, inventory, or otherwise handle drugs collected.¶
(4) A pharmacy must not dispose of drugs from pharmacy stock in a collection receptacle.¶
(5) The liner must be inserted and removed from a locked collection receptacle only by or under the supervision of two employees of the pharmacy. Upon removal, the liner must be immediately sealed, and the pharmacy employees must document their participation in the insertion and removal of each liner from a collection receptacle on a log. Sealed liners must not be opened, analyzed, or penetrated at any time by the pharmacy or pharmacy personnel.¶
(6) Liners that have been removed from a collection receptacle and immediately sealed must be directly transferred, or otherwise stored in a secured, locked location in the pharmacy for no longer than 14 days prior to being transferred, by two pharmacy personnel to a registered drug distribution agent (such as registered UPS, FedEx, or USPS) or a reverse wholesaler registered with the DEA and the board.¶
(7) Any tampering with a collection receptacle, liner or theft of deposited drugs must be reported to the board in writing within one day of discovery.¶
(8) A pharmacy must maintain all drug disposal records for a minimum of 3 years.¶
(9) Authorized collectors are required to comply with the following federal and state laws:¶
(a) ORS 459A.200, ORS 459A.203, ORS 459A.206, ORS 459A.209, ORS 459A.212, ORS 459A.215, ORS 459A.218, ORS 459A.221, ORS 459A.224, ORS 459A.227, ORS 459A.230, ORS 459A.233, ORS 459A.236, ORS 459A.239, ORS 459A.242, ORS 459A.245, ORS 459A.248, ORS 459A.251, ORS 459A.254, ORS 459A.257, ORS 459A.260, ORS 459A.263, and ORS 459A.266;¶
(b) OAR 340-098-0000, OAR 340-098-0010, OAR 340-098-0300, OAR 340-098-0350, OAR 340-098-0370, and OAR 340-098-0390;¶
(c) 21 CFR 1317.30 (v. 04/01/2024~~4~~5), 21 CFR 1317.35 (v. 04/01/2024~~4~~5), 21 CFR 1317.40 (v. 04/01/2024~~4~~5), 21 CFR 1317.55 (v. 04/01/2024~~4~~5), 21 CFR 1317.60 (v. 04/01/2024~~4~~5), 21 CFR 1317.65 (v. 04/01/2024~~4~~5), 21 CFR 1317.70 (v. 04/01/2024~~4~~5), 21 CFR 1317.75 (v. 04/01/2024~~4~~5), 21 CFR 1317.80 (v. 04/01/2024~~4~~5), and 21 CFR 1317.85 (v. 04/01/2024~~4~~5); and¶
(d) 21 USC 822 (v. 0~~3~~2/2~~5~~6/2025~~5~~6) and 21 USC 822a (v. 0~~3~~2/2~~5~~6/2025~~5~~6).¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205, ORS 459A.266
Statutes/Other Implemented: ORS 689.305, ORS 459A.203, ORS 459A.215, ORS 495A.218

AMEND: 855-041-1092

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-041-1092
Retail Drug Outlet Pharmacy Closures: Temporary, Permanent or Emergency
(1) Temporary Closing. Unless subject to an exemption in OAR 855-041-1092(3), when a Retail Drug Outlet pharmacy is temporarily closed to the public the pharmacy must:¶
(a) Post notification of closure on each pharmacy entrance as soon as the need to deviate from the posted hours is known by the pharmacy, but no later than 2 hours after the temporary closure begins. The posting must include:¶
(A) Estimated period of time the pharmacy will be closed; and¶
(B) Options for prescription pick-up (e.g. another local pharmacy, contact prescriber for new prescription, reverse processed prescriptions).¶
(b) Post notification of closure on each telephone greeting and pharmacy operated internet (e.g. website, social media, mobile applications) as soon as possible. The posting must include:¶
(A) Estimated period of time the pharmacy will be closed; and¶
(B) Options for prescription pick-up (e.g. another local pharmacy, contact prescriber for new prescription, reverse processed prescriptions).¶
(c) If the pharmacy is temporarily closed greater than 2 consecutive business days, notify the board office as soon as possible but no later than 72 hours after the temporary closure begins with the date and time the closure began, anticipated date and time of re-opening, and the reason for the temporary closure.¶
(d) Federal and state holidays are exempt from the requirements of (1).¶
(2) Permanent Closing. If a Retail Drug Outlet pharmacy is permanently closing to the public, the pharmacy must:¶
(a) Prior to closing, the pharmacy must comply with the following:¶
(A) Provide notification to each patient who has filled a prescription within the previous 12 months. This notification must be made a minimum of 15 calendar days prior to closing and must include:¶
(i) The last day the pharmacy will be open;¶
(ii) Name, address and telephone number of the pharmacy that will take possession of the pharmacy records or the person who will serve as the custodian of records;¶
(iii) Instructions on how patients can arrange for transfer of their pharmacy records to a pharmacy of their choice; and¶
(iv) The last day a transfer may be initiated.¶
(B) The notification must be made via:¶
(i) Distribution by direct mail or written notice with each prescription dispensed;¶
(ii) Public notice in a newspaper of general circulation, if available, in the area served by the pharmacy; and¶
(iii) Posting a closing notice on each pharmacy entrance, on each telephone greeting, and pharmacy-operated internet (e.g. website, social media, mobile applications).¶
(iv) In addition to (i), (ii) and (iii), the pharmacy may also provide notification via email or text.¶
(C) Provide any new patients filling prescriptions during the 15 calendar day period prior to the pharmacy closing with written notification that includes:¶
(i) The last day the pharmacy will be open;¶
(ii) Name, address and telephone number of the pharmacy to which pharmacy records will be transferred or the person who will serve as the custodian of pharmacy records;¶
(iii) Instructions on how patients can arrange for transfer of their pharmacy records to a pharmacy of their choice; and¶
(iv) The last day a transfer may be initiated.¶
(D) Notify DEA of any controlled substances being transferred to another registrant as specified in 21 CFR 1301.52 (v. 04/01/2024<u>5</u>).¶
(b) On the date of closing or up to 24 hours after the permanent closure begins, the Pharmacist-in-charge must comply with the following:¶
(A) Complete and document an inventory of all controlled substances.¶
(B) If the pharmacy dispenses prescriptions:¶
(i) Transfer the prescription drug order files, including refill information, and patient medication records to a licensed pharmacy or to an Oregon licensed Pharmacist who will serve as the custodian of records;¶

(ii) Update the pharmacy operating status with each electronic prescribing vendor; and¶
(iii) Remove all signs and symbols indicating the presence of the pharmacy including pharmacy-operated internet (e.g. website, social media, mobile applications).¶
(c) After closing. Within 30 calendar days after the closing of the pharmacy, the Pharmacist-in-charge must:¶
(A) Complete and document an inventory of all non-controlled drugs and devices.¶
(B) Remove all prescription and non-prescription drugs, devices, and related supplies from the pharmacy by one or a combination of the following methods:¶
(i) Return to manufacturer or supplier (credit or disposal);¶
(ii) Transfer (sell or give away) to a licensed healthcare professional or outlet who is legally authorized to possess drugs; or¶
(iii) Destroy and document the destruction by two board licensees. For controlled substances, the registrant must comply with 21 CFR 1304.21 (v. 04/01/20245), 21 CFR 1304.22 (v. 04/01/20245), 21 CFR 1317.05 (v. 04/01/20245), 21 CFR 1317.90 (v. 04/01/20245) and 21 CFR 1317.95 (v. 04/01/20245).¶
(C) Provide the board a written notice of the closing on a board prescribed form which includes the following information:¶
(i) Date of closing to the public and discontinuance of the business;¶
(ii) Date and time the inventory of all prescription drugs and devices was conducted;¶
(iii) Name, address, phone number and applicable registration number where all legend and controlled substances possessed by the pharmacy were transferred or disposed;¶
(iv) If drugs were destroyed, name and license numbers of individuals that who witnessed the destruction;¶
(v) If the pharmacy is registered to possess controlled substances, confirmation that the pharmacy complied with all applicable federal requirements in 21 CFR 1301.52 (v. 04/01/20245) for discontinuing operation as a pharmacy that dispenses controlled substances.¶
(vi) The name, address and phone number of the pharmacy that took possession of the pharmacy records or the Oregon licensed Pharmacist who is serve as the custodian of pharmacy records which must be maintained according to OAR 855-041-1160;¶
(vii) Confirmation all pharmacy labels and blank prescriptions were destroyed;¶
(viii) Confirmation all signs and symbols indicating the presence of the pharmacy including pharmacy-operated internet (e.g. website, social media, mobile applications) have been removed; and¶
(ix) Confirmation that each registration certificate issued to the pharmacy by the board has been mailed to the board office.¶
(D) Once the pharmacy has notified the board that the pharmacy is permanently closed, the license may not be renewed. The pharmacy may apply for a new license as specified in OAR 855-041-1080.¶
(E) Unless a registration has expired, the registration will remain active until the board has notified the registrant that the notice of permanent closure has been received and the registration has been lapsed.¶
(3) Emergency closing. If a Retail Drug Outlet pharmacy is closed suddenly due to fire, destruction, natural disaster, death, property seizure, eviction, bankruptcy, inclement weather, or other emergency circumstances and the Pharmacist-in-charge cannot provide notification as required in (1), the Pharmacist-in-charge must comply with the provisions of (1) as far in advance or as soon after the closing as allowed by the circumstances.¶
(4) Non-resident Retail Drug Outlet pharmacies are exempt from (1)-(3) and must follow laws and rules in the pharmacy's state of residence pertaining to temporary, permanent and emergency closures. The non-resident pharmacy must provide the board a written notice of the closing within 30 calendar days on a form prescribed by the board which includes the following information:¶
(a) Date of closing to the public and discontinuance of the business;¶
(b) If the pharmacy dispenses prescriptions, the name, address and phone number of the pharmacy or Oregon licensed Pharmacist who will serve as the custodian of records for Oregon patients to which the prescriptions, including refill information, and patient medication records were transferred; and¶
(c) Confirmation that each registration certificate issued to the pharmacy by the board has been mailed to the board office.¶
(5) The board may conduct an inspection to verify all requirements in subsection (1), (2), (3) and (4) of this section have been completed.¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205, ORS 475.035
Statutes/Other Implemented: ORS 689.205

AMEND: 855-041-1145

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055.Revises referenced versions of the Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-041-1145
New Containers ¶

Each pharmacy must dispense a drug in a new container that complies with the current provisions of the Poison Prevention Packaging Act in 16 CFR 1700 (v. 01/01/2024~~4~~5), 16 CFR 1701 (v. 01/01/2024~~4~~5), and 16 CFR 1702 (v. 01/01/2024~~4~~5).¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 689.155

AMEND: 855-041-7050

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-041-7050
Definitions - Long Term Care Pharmacy ¶

As used in OAR 855-041-7000 through 855-041-7080:¶
(1) "Long term care facility" means a facility with permanent facilities that include inpatient beds, providing medical services, including nursing services but excluding surgical procedures except as may be permitted by the rules of the director, to provide treatment for two or more unrelated patients. "Long Term Care facility" includes skilled nursing facilities and intermediate care facilities but may not be construed to include facilities licensed and operated pursuant to ORS 443.400 to 443.455.¶
(2) For the purposes of Schedule II prescriptions in 21 CFR 1306.11 (v. 04/01/2024~~4~~5), 21 CFR 1306.12 (v. 04/01/2024~~4~~5), 21 CFR 1306.13 (v. 04/01/2024~~4~~5), 21 CFR 1306.14 (v. 04/01/2024~~4~~5), and 21 CFR 1306.15 (v. 04/01/2024~~4~~5), the DEA definition of "long term care facility" as defined in 21 CFR 1300.01 (v. 04/01/2024~~4~~5) includes "community-based care facilities."¶
(3) "Community Based Care Facility" means a home, facility or supervised living environment licensed or certified or otherwise recognized by an agency of the state of Oregon which provides 24-hour care, supervision, and assistance with medication administration. These include but are not limited to Adult Foster Homes, Residential Care Facilities (RCF), Assisted Living Facilities (ALF), Intermediate Care Facilities for Individuals with Intellectual Disabilities and Inpatient Hospice.¶
(4) "Pharmaceutical Care" means the responsible provision of any or all of the following services by the pharmacist:¶
(a) Develop and maintain policies and procedures for pharmaceutical services;¶
(b) Provide direction and oversight regarding all aspects of the acquisition, disposition, handling, storage, and administration of drugs including but not limited to the following:¶
(A) Receipt and interpretation of physician's orders;¶
(B) Ordering and receiving of medications;¶
(C) Handling of emergency drugs and supplies;¶
(D) Labeling of all drugs;¶
(E) Selection of drug delivery systems;¶
(F) Development of systems to provide timely delivery of drugs and supplies;¶
(G) Monitoring of drug storage conditions and expiration dates;¶
(H) Monitoring accuracy and efficiency of medication administration and compliance with physician's orders;¶
(I) Establishing and monitoring of appropriate record keeping;¶
(J) Accountability of controlled substances;¶
(K) Return, release, and/or destruction of discontinued or outdated drugs; and¶
(L) Compliance with state and federal laws and regulations related to pharmaceutical services and medication management.¶
(c) Provide training and in-service education to facility staff;¶
(d) Perform drug regimen review for each resident on a regularly scheduled basis for the purpose of promoting therapeutic appropriateness and achieving the desired drug therapy outcomes by identifying issues such as:¶
(A) Over-utilization or underutilization;¶
(B) Therapeutic duplication;¶
(C) Drug-disease contraindications;¶
(D) Drug-drug interactions;¶
(E) Incorrect drug, drug dosage or duration of drug treatment;¶
(F) Drug-allergy interaction;¶
(G) Clinical abuse/misuse;¶
(H) Untreated indication;¶
(I) Monitoring and assessing of drug therapy outcomes;¶
(e) Communicate effectively with residents' physicians and facility staff; and¶
(f) Participate in resident care planning. ¶

[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 689.305

AMEND: 855-080-0020

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the United States Code (USC).

CHANGES TO RULE:

855-080-0020
Schedules ¶

Pursuant to ORS 475.005(6) those drugs and their immediate precursors classified in Schedules I through V under the Federal Controlled Substances Act, 21 USC 811 (v. 0~~3~~2/2~~5~~6/202~~5~~6), 21 USC 812 (v. 0~~3~~2/2~~5~~6/202~~5~~6) and as amended by the board pursuant to ORS 475.035 are the controlled substances for purposes of regulation and control under the Act. Those schedules are set out in OAR 855-080-0021 through 855-080-0026.¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 475.035

AMEND: 855-080-0021

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-080-0021
Schedule I ¶

(1) Schedule I consists of the drugs and other substances, by whatever official, common, usual, chemical, or brand name designated, listed in 21 CFR 1308.11 (v. 04/01/2024~~4~~5), and unless specifically exempt or unless listed in another schedule, any quantity of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation:¶
(a) 1,4-butanediol;¶
(b) Gamma-butyrolactone¶
(c) Methamphetamine, except as listed in OAR 855-080-0022;¶
(d) Dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide (U-47700)¶
(e) 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]piperidin-2-ylidene]benzenesulfonamide (W-18) and positional isomers thereof, and any substituted derivative of W-18 and its positional isomers, and their salts, by any substitution on the piperidine ring (including replacement of all or part of the nitrophenylethyl group), any substitution on or replacement of the sulfonamide, or any combination of the above that are not FDA approved drugs, unless specifically excepted or when in the possession of an FDA registered manufacturer or a registered research facility, or a person for the purpose of sale to an FDA registered manufacturer or a registered research facility.¶
(f) Substituted derivatives of cathinone and methcathinone that are not listed in OARs 855-080-0022 through 0026 (Schedules II through V) or are not FDA approved drugs, including but not limited to,¶
(A) Methylmethcathinone (Mephedrone);¶
(B) Methylenedioxypyrovalerone (MDPV);¶
(C) Methylenedioxymethylcathinone (Methylone);¶
(D) 2-Methylamino-3',4'-(methylenedioxy)-butyrophenone (Butylone);¶
(E) Fluoromethcathinone (Flephedrone);¶
(F) 4-Methoxymethcathinone (Methedrone).¶
(2) Schedule I also includes any compounds in the following structural classes (2a-2k) and their salts, that are not FDA approved drugs, unless specifically excepted or when in the possession of an FDA registered manufacturer or a registered research facility, or a person for the purpose of sale to an FDA registered manufacturer or a registered research facility:¶
(a) Naphthoylindoles: Any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include but are not limited to: JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, AM-1220, MAM-2201 and AM-2201;¶
(b) Phenylacetylindoles: Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent. Examples of this structural class include but are not limited to: JWH-167, JWH -201, JWH-203, JWH-250, JWH-251, JWH-302 and RCS-8;¶
(c) Benzoylindoles: Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples of this structural class include but are not limited to: RCS-4, AM-694, AM-1241, and AM-2233;¶
(d) Cyclohexylphenols: Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring whether or not substituted in the cyclohexyl ring to any extent. Examples of this structural class include but are not limited to: CP 47,497 and its C8 homologue (cannabicyclohexanol);¶
(e) Naphthylmethylindoles: Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;¶
(f) Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the

nitrogen atom of the pyrrole ring whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent;¶
(g) Naphthylmethylindenes: Any compound containing a 1-(1-naphthylmethyl) indene structure with substitution at the 3-position of the indene ring whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent;¶
(h) Cyclopropanoylindoles: Any compound containing an 3-(cyclopropylmethanoyl)indole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent and whether or not substituted in the cyclopropyl ring to any extent. Examples of this structural class include but are not limited to: UR-144, XLR-11 and A-796,260;¶
(i) Adamantoylindoles: Any compound containing a 3-(1-adamantoyl)indole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent. Examples of this structural class include but are not limited to: AM-1248 and AB-001;¶
(j) Adamantylindolecarboxamides: Any compound containing an N-adamantyl-1-indole-3-carboxamide with substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent. Examples of this structural class include but are not limited to: STS-135 and 2NE1; and¶
(k) Adamantylindazolecarboxamides: Any compound containing an N-adamantyl-1-indazole-3-carboxamide with substitution at the nitrogen atom of the indazole ring, whether or not further substituted in the indazole ring to any extent and whether or not substituted in the adamantyl ring to any extent. Examples of this structural class include but are not limited to: AKB48.¶
(3) Schedule I also includes any other cannabinoid receptor agonist that is not listed in OARs 855-080-0022 through 0026 (Schedules II through V) is not an FDA approved drug or is exempted from the definition of controlled substance in ORS 475.005(6)(b)(A)-(E).¶
(4) Schedule I also includes any substituted derivatives of fentanyl that are not listed in OARs 855-080-0022 through 0026 (Schedules II through V) or are not FDA approved drugs, and are derived from fentanyl by any substitution on or replacement of the phenethyl group, any substitution on the piperidine ring, any substitution on or replacement of the propanamide group, any substitution on the phenyl group, or any combination of the above.¶
(5) Schedule I also includes any compounds in the following structural classes (a - b), and their salts, that are not listed in OARs 855-080-0022 through 0026 (Schedules II through V) or FDA approved drugs, unless specifically excepted or when in the possession of an FDA registered manufacturer or a registered research facility, or a person for the purpose of sale to an FDA registered manufacturer or a registered research facility:¶
(a) Benzodiazepine class: A fused 1,4-diazepine and benzene ring structure with a phenyl connected to the diazepine ring, with any substitution(s) or replacement(s) on the 1,4-diazepine or benzene ring, any substitution(s) on the phenyl ring, or any combination thereof. Examples of this structural class include but are not limited to: Clonazolam, Flualprazolam¶
(b) Thienodiazepine class: A fused 1,4-diazepine and thiophene ring structure with a phenyl connected to the 1,-4-diazepine ring, with any substitution(s) or replacement(s) on the 1,4-diazepine or thiophene ring, any substitution(s) on the phenyl ring, or any combination thereof. Examples of this structural class include but are not limited to: Etizolam¶
(6) Exceptions. The following are exceptions to subsection (1) of this rule:¶
(a) 1, 4-butanediol and gamma-butyrolactone when in the possession of a person for the purpose of its sale to a legitimate manufacturer of industrial products and the person is in compliance with the Drug Enforcement Administration requirements for List I Chemicals;¶
(b) 1, 4-butanediol and gamma-butyrolactone when in the possession of a person for the purpose of the legitimate manufacture of industrial products;¶
(c) The following substances per ORS 475.005(6)(b):¶
(A) The plant Cannabis family Cannabaceae;¶
(B) Any part of the plant Cannabis family Cannabaceae, whether growing or not;¶
(C) Resin extracted from any part of the plant Cannabis family Cannabaceae;¶
(D) The seeds of the plant Cannabis family Cannabaceae; or¶
(E) Any compound, manufacture, salt, derivative, mixture or preparation of a plant, part of a plant, resin or seed described in this paragraph. ¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 475.005, ORS 475.035, ORS 475.055, ORS 475.065

AMEND: 855-080-0022

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-080-0022
Schedule II ¶

Schedule II consists of the drugs and other substances by whatever official, common, usual, chemical, or brand name designated, listed in 21 CFR 1308.12 (v. 04/01/2024~~4~~5) and any quantity of methamphetamine, when in the form of a FDA approved product containing methamphetamine, its salts, isomers, and salts of its isomers as an active ingredient for the purposes of currently accepted medical use. ¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 475.005, ORS 475.035, ORS 475.055, ORS 475.065

AMEND: 855-080-0023

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-080-0023
Schedule III ¶

Schedule III consists of the drugs and other substances by whatever official, common, usual, chemical, or brand name designated, listed in 21 CFR 1308.13 (v. 04/01/2024~~4~~5). ¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205, ORS 475.973
Statutes/Other Implemented: ORS 475.035

AMEND: 855-080-0024

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-080-0024
Schedule IV ¶

Schedule IV consists of the drugs and other substances, by whatever official, common, usual, chemical, or brand name designated, listed in 21 CFR 1308.14 (v. 04/01/2024~~4~~5), unless specifically excepted or listed in another schedule. ¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 475.035

AMEND: 855-080-0026

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055.Revises referenced versions of the Code of Federal Regulations (CFR)

CHANGES TO RULE:

855-080-0026
Schedule V ¶

Schedule V consists of the drugs and other substances, by whatever official, common, usual, chemical, or brand name designated, listed in 21 CFR 1308.15 (v. 04/01/2024~~4~~5); and¶
(1) Products containing pseudoephedrine or the salts of pseudoephedrine as an active ingredient.¶
(2) Products containing ephedrine or the salts of ephedrine as an active ingredient.¶
(3) Products containing phenylpropanolamine or the salts of phenylpropanolamine as an active ingredient.¶
(4) In order to provide non-prescription pseudoephedrine or ephedrine to a purchaser, a pharmacy must:¶
(a) Store all pseudoephedrine and ephedrine behind the pharmacy counter in an area that is inaccessible to the public;¶
(b) Utilize an electronic system meeting the requirements under ORS 475.230;¶
(c) Train individuals who are responsible for providing pseudoephedrine or ephedrine to purchasers on the requirements of the Combat Methamphetamine Epidemic Act of 2005 (Title VII of the USA PATRIOT Improvement and Reauthorization Act of 2005, P.L. 109-177), the Combat Methamphetamine Enhancement Act of 2010, P.L. 111-268, and use of the electronic system as described in ORS 475.230;¶
(d) Ensure that only a Pharmacist, Intern, Certified Oregon Pharmacy Technician or Pharmacy Technician provides pseudoephedrine or ephedrine to the purchaser after:¶
(A) Verifying that the purchaser is 18 years of age or older;¶
(B) Verifying the identity of the purchaser with valid government-issued photo identification; and¶
(C) Confirming the purchase is allowed via the electronic system; and¶
(e) Maintain an electronic log for at least three years from the date of the transaction that documents the following elements:¶
(A) Date and time of the purchase;¶
(B) Name, address and date of birth of the purchaser;¶
(C) Form of government-issued photo identification and the identification number used to verify the identity of the purchaser;¶
(D) Name of the government agency that issued the photo identification in (C);¶
(E) Name of product purchased;¶
(F) Quantity in grams of product purchased;¶
(G) Name or initials of Pharmacist, Intern, Certified Oregon Pharmacy Technician or Pharmacy Technician who provides the drug; and¶
(H) Signature of the purchaser. The signature of the purchaser may be recorded on a written log that also contains the transaction ID generated by the electronic system.¶
(5) All sales of pseudoephedrine or ephedrine are subject to the following quantity limits and restrictions:¶
(a) No more than 3.6 grams in a 24-hour period, no more than 9 grams in a 30-day period without regard to the number of transactions; and¶
(b) For non-liquids, product packaging is limited to blister packs containing no more than 2 dosage units per blister. Where blister packs are not technically feasible, the product must be packaged in unit dose packets or pouches.¶
(6) Sections (4) and (5) do not apply to a pseudoephedrine or ephedrine when the drug is dispensed pursuant to a prescription.¶
(7)-Each pharmacy, Pharmacist, Intern, Certified Oregon Pharmacy Technician and Pharmacy Technician involved in the provision of pseudoephedrine or ephedrine to a purchaser must comply with the provisions of 21 CFR 1314.01 (v. 04/01/2024~~4~~5), 21 CFR 1314.02 (v. 04/01/2024~~4~~5), 21 CFR 1314.03 (v. 04/01/2024~~4~~5), 21 CFR 1314.05 (v. 04/01/2024~~4~~5), 21 CFR 1314.10 (v. 04/01/2024~~4~~5), 21 CFR 1314.15 (v. 04/01/2024~~4~~5), 21 CFR 1314.20 (v. 04/01/2024~~4~~5), 21 CFR 1314.25, (v. 04/01/2024~~4~~5); 21 CFR 1314.30 (v. 04/01/2024~~4~~5), 21 CFR 1314.35 (v. 04/01/2024~~4~~5), 21 CFR 1314.40 (v. 04/01/2024~~4~~5), 21 CFR 1314.42 (v. 04/01/2024~~4~~5), 21 CFR 1314.45 (v. 04/01/2024~~4~~5); and 21 CFR 1314.50 (v. 04/01/2024~~4~~5).¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205, ORS 475.230

Statutes/Other Implemented: ORS 475.035, ORS 475.230

AMEND: 855-080-0028

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055.Revises referenced versions of the Code of Federal Regulations (CFR) and Table of Exempted Prescription Products.

CHANGES TO RULE:

855-080-0028
Excluded or Exempted Substances ¶

(1) The board adopts the excluded substances list found in 21 CFR 1308.22 (v. 04/01/2024~~4~~5).¶
(2) The board adopts the exempt chemical preparations list found in 21 CFR 1308.24 (v. 04/01/2024~~4~~5).¶
(3) The board adopts the exempted prescription products list in the Table of Exempted Prescription Products (v. ~~0~~1~~2~~/~~11~~03/2025) pursuant to 21 CFR 1308.32 (v. 04/01/2024~~4~~5).¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205, ORS 475.035
Statutes/Other Implemented: ORS 689.155, ORS 475.035

AMEND: 855-080-0031

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-080-0031
Registration Requirements ¶

(1) Every person who manufactures, delivers, or dispenses any controlled substance within this state or who proposes to engage in the manufacture, delivery or dispensing of any controlled substance within this state must obtain a controlled substance registration annually issued by the State Board of Pharmacy.¶
(2) The board adopts the exceptions to registration for distribution by dispenser to another practitioner pursuant to 21 CFR 1307.11 (v. 04/01/2024~~4~~5).¶
(3) The board adopts the exceptions to registration for the incidental manufacture of controlled substances pursuant to 21 CFR 1307.13 (v. 04/01/2024~~4~~5). ¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.155, ORS 689.205
Statutes/Other Implemented: ORS 475.125

AMEND: 855-080-0065

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-080-0065
Security ¶

(1) All applicants and registrants as applicable to the registration classification must comply with the security requirements of 21 CFR 1301.01 (v. 04/01/2024~~4~~5), 21 CFR 1301.02 (v. 04/01/2024~~4~~5), 21 CFR 1301.71 (v. 04/01/2024~~4~~5), 21 CFR 1301.72 (v. 04/01/2024~~4~~5), 21 CFR 1301.73 (v. 04/01/2024~~4~~5), 21 CFR 1301.74 (v. 04/01/2024~~4~~5), 21 CFR 1301.75 (v. 04/01/2024~~4~~5), 21 CFR 1301.76 (v. 04/01/2024~~4~~5), 21 CFR 1301.77 (v. 04/01/2024~~4~~5), 21 CFR 1301.90 (v. 04/01/2024~~4~~5), 21 CFR 1301.91 (v. 04/01/2024~~4~~5), 21 CFR 1301.92 (v. 04/01/2024~~4~~5), and 21 CFR 1301.93 (v. 04/01/2024~~4~~5).¶
(2) The security requirements of (1) of this rule apply to all controlled substances, as defined in these rules, including ephedrine, pseudoephedrine, and phenylpropanolamine.¶
(3) Applicants and registrants must guard against theft and diversion of ephedrine, pseudoephedrine, and phenylpropanolamine.¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 475.135, ORS 475.125

AMEND: 855-080-0070

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the United States Code (USC) and Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-080-0070
Records and Inventory ¶

(1) All registrants must, as applicable to the registration classification, keep records and maintain inventories in compliance with 21 USC 827 (v. 03/2/25/2025/6); 21 CFR 1304.01 (v. 04/01/2024/5), 21 CFR 1304.02 (v. 04/01/2024/5), 21 CFR 1304.03 (v. 04/01/2024/5), 21 CFR 1304.04 (v. 04/01/2024/5), 21 CFR 1304.05 (v. 04/01/2024/5), 21 CFR 1304.06 (v. 04/01/2024/5); 21 CFR 1304.11 (v. 04/01/2024/5); 21 CFR 1304.21 (v. 04/01/2024/5), 21 CFR 1304.22 (v. 04/01/2024/5), 21 CFR 1304.23 (v. 04/01/2024/5), 21 CFR 1304.24 (v. 04/01/2024/5), 21 CFR 1304.25 (v. 04/01/2024/5), 21 CFR 1304.26 (v. 04/01/2024/5); 21 CFR 1304.31 (v. 04/01/2024/5), 21 CFR 1304.32 (v. 04/01/2024/5), 21 CFR 1304.33 (v. 04/01/2024/5).¶
(2) A written inventory of all controlled substances must be taken by registrants annually within 367 days of the last written inventory.¶
(3) All such records must be maintained for a period of three years.¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 475.035, ORS 689.205
Statutes/Other Implemented: ORS 475.165

AMEND: 855-080-0075

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the United States Code (USC) and Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-080-0075
Orders for Schedule I and II Controlled Substances
Controlled substances in Schedules I and II must be distributed by a registrant to another registrant only pursuant to an order form or electronic order in compliance with 21 USC 828 (v. 0~~4/01~~2/26/2024~~6~~) and 21 CFR 1305.01 (v. 04/01/2024~~5~~), 21 CFR 1305.02 (v. 04/01/2024~~5~~), 21 CFR 1305.03 (v. 04/01/2024~~5~~), 21 CFR 1305.04 (v. 04/01/2024~~5~~), 21 CFR 1305.05 (v. 04/01/2024~~5~~), 21 CFR 1305.06 (v. 04/01/2024~~5~~), 21 CFR 1305.07 (v. 04/01/2024~~5~~); 21 CFR 1305.11 (v. 04/01/2024~~5~~), 21 CFR 1305.12 (v. 04/01/2024~~5~~), 21 CFR 1305.13 (v. 04/01/2024~~5~~), 21 CFR 1305.14 (v. 04/01/2024~~5~~), 21 CFR 1305.15 (v. 04/01/2024~~5~~), 21 CFR 1305.16 (v. 04/01/2024~~5~~), 21 CFR 1305.17 (v. 04/01/2024~~5~~), 21 CFR 1305.18 (v. 04/01/2024~~5~~), 21 CFR 1305.19 (v. 04/01/2024~~5~~), 21 CFR 1305.20 (v. 04/01/2024~~5~~); 21 CFR 1305.21 (v. 04/01/2024~~5~~), 21 CFR 1305.22 (v. 04/01/2024~~5~~), 21 CFR 1305.23 (v. 04/01/2024~~5~~), 21 CFR 1305.24 (v. 04/01/2024~~5~~), 21 CFR 1305.25 (v. 04/01/2024~~5~~), 21 CFR 1305.26 (v. 04/01/2024~~5~~), 21 CFR 1305.27 (v. 04/01/2024~~5~~), 21 CFR 1305.28 (v. 04/01/2024~~5~~), and 21 CFR 1305.29 (v. 04/01/2024~~5~~).¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 475.175

AMEND: 855-080-0085

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-080-0085
Prescription Requirements ¶

(1) Registrants, practitioners and Pharmacists as specified therein in the issuance, preparation, labeling, dispensing, recordkeeping and filing of prescriptions for controlled substances must comply with the provisions of 21 CFR 1306.01 (v. 04/01/20245), 21 CFR 1306.02 (v. 04/01/20245), 21 CFR 1306.03 (v. 04/01/20245), 21 CFR 1306.04 (v. 04/01/20245), 21 CFR 1306.05 (v. 04/01/20245), 21 CFR 1306.06 (v. 04/01/20245), 21 CFR 1306.07 (v. 04/01/20245), 21 CFR 1306.08 (v. 04/01/20245), 21 CFR 1306.09 (v. 04/01/20245); 21 CFR 1306.11 (v. 04/01/20245), 21 CFR 1306.12 (v. 04/01/20245), 21 CFR 1306.13 (v. 04/01/20245), 21 CFR 1306.14 (v. 04/01/20245), 21 CFR 1306.15 (v. 04/01/20245); 21 CFR 1306.21 (v. 04/01/20245), 21 CFR 1306.22 (v. 04/01/20245); 21 CFR 1306.23 (v. 04/01/20245), 21 CFR 1306.24 (v. 04/01/20245), 21 CFR 1306.25 (v. 04/01/20245), 21 CFR 1306.27 (v. 04/01/20245); and 21 CFR 1304.03(d) (v. 04/01/20245).¶
(2) Controlled substances listed in 21 CFR 1308.15 (v. 04/01/20245) as ~~s~~Schedule V are prescription drugs.¶
(3) Pseudoephedrine and ephedrine may be:¶
(a) Provided to a patient without a prescription under ORS 475.230.¶
(b) Dispensed to patient pursuant to a prescription which must follow the provisions of 21 CFR 1306.21 (v. 04/01/20245), 21 CFR 1306.22 (v. 04/01/20245); 21 CFR 1306.23 (v. 04/01/20245), 21 CFR 1306.24 (v. 04/01/20245), 21 CFR 1306.25 (v. 04/01/20245), and 21 CFR 1306.27 (v. 04/01/20245).¶
(4) For a Schedule II controlled substance prescription, a Pharmacist may:¶
(a) Add the patient's address based on information provided by the patient or patient's agent with appropriate verification;¶
(b) Amend or add the following information after consultation with and agreement of the prescriber:¶
(A) Drug strength; ¶
(B) Dosage form;¶
(C) Drug quantity;¶
(D) Directions for use;¶
(E) Prescriber's address; and¶
(F) Prescriber's DEA registration number.¶
(c) Amend the following information after consultation with and agreement of the prescriber, the:¶
(A) Date the prescription was issued; and¶
(B) Date the prescription can be filled.¶
(d) For (b) and (c), the Pharmacist must document on the prescription the date of the prescriber's authorization, the amendment or addition authorized, and the Pharmacist's identity. ¶
(5) For a Schedule II controlled substance prescription, a Pharmacist must not change the patient's name, the controlled substance prescribed except for generic substitution, and the name or signature of the prescriber. ¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 475.185, ORS 475.188

AMEND: 855-115-0130

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-115-0130
Responsibilities: Practicing Pharmacy for a Drug Outlet
(1) When practicing pharmacy per ORS 689 for a Drug Outlet, each Pharmacist must:¶
(a) Be responsible for the daily conduct, operation, management and control of the Drug Outlet pharmacy;¶
(b) Ensure that only a Pharmacist has access to the Drug Outlet pharmacy when the pharmacy is closed, except as permitted in OAR 855-041-6310;¶
(c) Ensure each prescription contains all the elements required in OAR 855-041 or OAR 855-139; ¶
(d) Ensure the patient record contains the elements required in OAR 855-041 or OAR 855-139;¶
(e) Ensure prescriptions, prescription refills, and drug orders are dispensed:¶
(A) Accurately;¶
(B) To the correct party;¶
(C) Pursuant to a valid prescription; ¶
(D) Pursuant to a valid patient-practitioner relationship; and ¶
(E) For a legitimate medical purpose;¶
(f) Ensure the Drug Outlet pharmacy is operated in a professional manner at all times; ¶
(g) Ensure the drug outlet reports data as required by federal and state regulations, including but not limited to:¶
(A) Prescription Drug Monitoring Program (PDMP) per ORS 413A.890, ORS 413A.895, ORS 413A.896, ORS 413A.898, and OAR 333-023;¶
(B) Death with Dignity per ORS 127.800, ORS 127.805, ORS 127.810, ORS 127.815, ORS 127.820, ORS 127.825, ORS 127.830, ORS 127.835, ORS 127.840, ORS 127.845, ORS 127.850, ORS 127.855, ORS 127.860, ORS 127.865, ORS 127.870, ORS 127.875, ORS 127.880, ORS 127.885, ORS 127.890, ORS 127.892, ORS 127.895, ORS 127.897, and OAR 333-009;¶
(C) Controlled substances per 21 CFR 1301.74 (v. 04/01/2024~~4~~5); and¶
(D) Listed chemicals per 21 CFR 1310.05 (v. 04/01/2024~~4~~5); and¶
(2) A Pharmacist who utilizes licensees remotely, must comply with OAR 855-041-3200 through OAR 855-041-3250.¶
(3) When engaging in the practice of pharmacy per ORS 689, each Pharmacist may delegate final verification of drug and drug dosage, device, or product to a Certified Oregon Pharmacy Technician or Pharmacy Technician per ORS 689.703 when the following conditions are met:¶
(a) The Pharmacist utilizes reasonable professional judgment to determine that a Certified Oregon Pharmacy Technician or Pharmacy Technician may perform final verification;¶
(b) The Certified Oregon Pharmacy Technician or Pharmacy Technician does not use discretion in conducting final verification;¶
(c) The Pharmacist delegating final verification is supervising the Certified Oregon Pharmacy Technician or Pharmacy Technician; and¶
(d) Ensure the Certified Oregon Pharmacy Technician or Pharmacy Technician is performing a physical final verification. ¶
(4) If the patient is relying on a standing order prescription issued by the Public Health Officer appointed under ORS 431.045, or a physician licensed under ORS chapter 677 who is employed by the Oregon Health Authority, to obtain a drug or device, the Pharmacist does not need to ensure that:¶
(a) There is a patient-practitioner relationship as required in subsection (1)(e)(D) of this rule; and¶
(b) The prescription contains the name and date of birth of the patient for whom the drug is prescribed.¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 689.155, ORS 689.703

AMEND: 855-120-0005

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced version of Accreditation Council for Pharmacy Education accredited colleges and schools of pharmacy.

CHANGES TO RULE:

855-120-0005
Definitions
(1) "ACPE accredited" means a college or school of pharmacy that is accredited, accredited with probation, pre-candidate or candidate status by Accreditation Council for Pharmacy Education (v. 0~~3~~2/2~~5~~7/202~~5~~6) including the Lebanese American University school in Byblos, Lebanon after 2002.¶
(2) "College of Pharmacy or School of Pharmacy (COP or SOP)" means an ACPE accredited college or school of pharmacy.¶
(3) "Healthcare Preceptor" means a pharmacist, or person with an active healthcare license in good standing that can independently practice pharmacy within the scope of their licensure and is licensed by the board to supervise the internship training of a licensed Intern.¶
(4) "Intern" means a person who is enrolled in or has completed a course of study at a board approved college or school of pharmacy and who is licensed with the board as an Intern.¶
(5) "Internship Program" means a professional experiential program that is approved by the board.¶
(6) "Internship Program Supervisor" is a Pharmacist licensed with the board as a Preceptor who supervises the Internship Program for a COP or SOP located in Oregon.¶
(7) "Other Preceptor" means a person who is not licensed as a pharmacist or other healthcare provider in Oregon and is licensed by the board to supervise the internship training of a licensed Intern.¶
(8) "Preceptor" means a Pharmacist or a person licensed by the board to supervise the internship training of a licensed Intern.¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 689.151, ORS 689.155

AMEND: 855-135-0001

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced version of CPE accredited by the Accreditation Council on Pharmaceutical Education (ACPE) and continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education (ACCME).

CHANGES TO RULE:

855-135-0001
Continuing Pharmacy Education: Definitions
(1) "Accredited program" means a structured continuing pharmacy education (CPE) program which has been reviewed and approved by a provider of:¶
(a) Continuing pharmacy education that is accredited by the Accreditation Council on Pharmaceutical Education (ACPE) (v. 0~~5~~2/27/202~~5~~6);¶
(b) Continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education (ACCME) or an ACCME-recognized State Medical Society (v. 0~~5~~2/27/202~~5~~6) as an American Medical Association (AMA) Category 1 CME program; or¶
(c) Continuing veterinary medical education (CVME) approved by the American Association of Veterinary State Boards Registry of Approved Continuing Education (AAVSB-RACE) as a medical program.¶
(2) "Board-approved program" means a structured continuing pharmacy education program which has been reviewed and approved by the board.¶
(3) "Certificate of completion" means a certificate or other official document issued to a participant certifying the successful completion of a continuing pharmacy education program.¶
(4) "Continuing Pharmacy Education" or "CPE" means an accredited or board-approved program designed to support the continuing development of Pharmacists, Interns, Certified Oregon Pharmacy Technicians or Pharmacy Technicians to maintain and enhance their competence applicable to the practice of pharmacy or the assistance of the practice of pharmacy. ¶
(5) "Contact hour" means sixty minutes of continuing pharmacy education. ¶
(6) "CPE Monitor" means the electronic tracking service of the ACPE and the National Association of Boards of Pharmacy (NABP) for monitoring continuing pharmacy education that Pharmacists, Interns, Certified Oregon Pharmacy Technicians and Pharmacy Technicians receive from participating providers;¶
(7) "Cultural competence" means the lifelong process of examining the values and beliefs and developing and applying an inclusive approach to health care practice in a manner that recognizes the content and complexities of provider-patient communication and interaction and preserves the dignity of individuals, families, and communities.¶
(a) Cultural competence applies to all patients.¶
(b) Culturally competent providers do not make assumptions on the basis of an individual's actual or perceived abilities, disabilities or traits whether inherent, genetic or developmental including: race, color, spiritual beliefs, creed, age, tribal affiliation, national origin, immigration or refugee status, marital status, socio-economic status, veteran's status, sexual orientation, gender identity, gender expression, gender transition status, level of formal education, physical or mental disability, medical condition or any consideration recognized under federal, state and local law.¶
(8) "Medication error prevention" means the prevention of events that may cause or lead to inappropriate medication use or patient harm, while the medication is in the control of the healthcare professional, patient, or consumer. ¶
(9) "Patient safety" means the prevention of healthcare related errors or the elimination or mitigation of patient injury caused by healthcare related errors. ¶
(10) "Pain management education program" means a specific one-hour web-based program developed by the Pain Management Commission of the Oregon Health Authority.¶
(11) "Pharmacy law" means the body of laws relating to pharmacy practice.¶
(12) "Structured continuing pharmacy education" or "Structured CPE" means education that includes defined learning objectives, qualified instructors, learning assessment, and a program evaluation.
Statutory/Other Authority: ORS 689.205, ORS 676.850
Statutes/Other Implemented: ORS 413.450, ORS 413.590, ORS 689.255, ORS 689.285, ORS 689.486, ORS 689.490

AMEND: 855-139-0145

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-139-0145
Outlet: Closure- Temporary, Permanent and Emergency
(1) Temporary Closing. Unless subject to an exemption in OAR 855-139-0145(3), when a RDSP is temporarily closed to the public the RDSP must:¶
(a) Post notification of closure on each RDSP entrance as soon as the need to deviate from the posted hours is known by the RDSP, but no later than 2 hours after the temporary closure begins. The posting must include:¶
(A) Estimated period of time the RDSP will be closed; and¶
(B) Options for prescription pick-up (e.g. another local pharmacy, contact prescriber for new prescription, reverse processed prescriptions).¶
(b) Post notification of closure on each telephone greeting and pharmacy operated internet (e.g. website, social media, mobile applications) as soon as possible. The posting must include:¶
(A) Estimated period of time the RDSP will be closed; and¶
(B) Options for prescription pick-up (e.g. another local pharmacy, contact prescriber for new prescription, reverse processed prescriptions).¶
(c) If the RDSP is temporarily closed greater than 2 consecutive business days, notify the board office as soon as possible but no later than 72 hours after the temporary closure begins with the date and time the closure began, anticipated date and time of re-opening, and the reason for the temporary closure.¶
(d) Federal and state holidays are exempt from the requirements of (1).¶
(2) Permanent Closing. If a RDSP is permanently closing to the public, the RDSP must:¶
(a) Prior to closing, the RDSP must comply with the following:¶
(A) Provide notification to each patient who has filled a prescription within the previous 12 months. This notification must be made a minimum of 15 calendar days prior to closing and must include:¶
(i) The last day the RDSP will be open;¶
(ii) Name, address and telephone number of the pharmacy to which pharmacy records will be transferred or the Oregon licensed Pharmacist who will serve as the custodian of records;¶
(iii) Instructions on how patients can arrange for transfer of their pharmacy records to a pharmacy of their choice; and¶
(iv) The last day a transfer may be initiated.¶
(B) The notification must be made via:¶
(i) Distribution by direct mail or written notification with each prescription dispensed;¶
(ii) Public notice in a newspaper of general circulation, if available, in the area served by the RDSP; and¶
(iii) Posting a closing notice at each building and each RDSP entrance, on each telephone greeting, and pharmacy-operated internet (e.g. website, social media, mobile applications).¶
(iv) In addition to (i), (ii) and (iii), the RDSP may also provide notification via email or text.¶
(C) Provide any new patients filling prescriptions during the 15-calendar day period prior to the RDSP closing with written notification that includes:¶
(i) The last day the RDSP will be open;¶
(ii) Name, address and telephone number of the pharmacy to which pharmacy records will be transferred or the Oregon licensed Pharmacist who will serve as the custodian of records;¶
(iii) Instructions on how patients can arrange for transfer of their pharmacy records to a pharmacy of their choice; and¶
(iv) The last day a transfer may be initiated.¶
(D) Notify DEA of any controlled substances being transferred to another registrant as specified in 21 CFR 1301.52 (v. 04/01/2024<u>5</u>).¶
(b) On the date of closing or up to 24 hours after the permanent closure begins, the pharmacist-in-charge must comply with the following:¶
(A) Complete and document an inventory of all controlled substances.¶
(B) If the RDSP dispenses prescriptions:¶
(i) Transfer the prescription drug order files, including refill information, and patient medication records to a licensed pharmacy or to an Oregon licensed Pharmacist who will serve as the custodian of records;¶

(ii) Update the RDSP operating status with each electronic prescribing vendor; and¶
(iii) Remove all signs and symbols indicating the presence of the RDSP including pharmacy-operated internet (e.g. website, social media, mobile applications).¶
(c) After closing. Within 30 calendar days after the closing of the RDSP, the pharmacist-in-charge must:¶
(A) Complete and document an inventory of all non-controlled drugs and devices.¶
(B) Remove all prescription and non-prescription drugs, devices, and related supplies from the RDSP by one or a combination of the following methods:¶
(i) Return to manufacturer or supplier (credit or disposal);¶
(ii) Transfer (sell or give away) to a licensed healthcare professional or outlet who is legally authorized to possess drugs; or¶
(iii) Destroy and document the destruction by two board licensees. For controlled substances, the registrant must comply with 21 CFR 1304.21 (v. 04/01/20245), 21 CFR 1304.22 (v. 04/01/20245), 21 CFR 1317.05 (v. 04/01/20245), 21 CFR 1317.90 (v. 04/01/20245) and 21 CFR 1317.95 (v. 04/01/20245).¶
(C) Provide the board a written notice of the closing on a board prescribed form which includes the following information:¶
(i) Date of closing to the public and discontinuance of the business;¶
(ii) Date and time the inventory of all prescription drugs and devices was conducted;¶
(iii) Name, address, phone number and applicable registration number where all legend and controlled substances possessed by the RDSP were transferred or disposed;¶
(iv) If drugs were destroyed, name and license numbers of individuals who witnessed the destruction;¶
(v) If the RDSP is registered to possess controlled substances, confirmation that the RDSP complied with all applicable federal requirements in 21 CFR 1301.52 (v. 04/01/20245) for discontinuing operation as a RDSP that dispenses controlled substances.¶
(vi) If the RDSP dispenses prescriptions, the name, address and phone number of the RDSP or Oregon licensed Pharmacist who will serve as the custodian of records to which the prescriptions, including refill information, and patient medication records were transferred;¶
(vii) Confirmation all RDSP labels and blank prescriptions were destroyed;¶
(viii) Confirmation all signs and symbols indicating the presence of the RDSP including pharmacy-operated internet (e.g. website, social media, mobile applications) have been removed; and¶
(ix) Confirmation that each registration certificate issued to the RDSP by the board has been mailed to the board office.¶
(D) Once the RDSP has notified the board that the RDSP is permanently closed, the license may not be renewed. The RDSP may apply for a new license as specified in OAR 855-139-0015.¶
(E) Unless a registration has expired, the registration will remain active until the board has notified the registrant that the notice of permanent closure has been received and the registration has been lapsed.¶
(3) Emergency closing. If the RDSP is closed suddenly due to fire, destruction, natural disaster, death, property seizure, eviction, bankruptcy, inclement weather, or other emergency circumstances and the pharmacist-in-charge cannot provide notification as required in (1), the ~~P~~pharmacist-in-charge must comply with the provisions of (1) as far in advance or as soon after the closing as allowed by the circumstances.¶
(4) The board may conduct an inspection to verify all requirements in subsection (1), (2), and (3) of this section have been completed. ¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 475.035, ORS 689.205, ORS 689.700
Statutes/Other Implemented: ORS 689.155, ORS 689.700

AMEND: 855-139-0350

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-139-0350
Dispensing: Containers
Each pharmacy must dispense a drug in a new container that complies with the current provisions of the Poison Prevention Packaging Act in 16 CFR 1700 (v. 01/01/2024~~4~~5), 16 CFR 1701 (v. 01/01/2024~~4~~5), and 16 CFR 1702 (v. 01/01/2024~~4~~5).¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 689.155

AMEND: 855-139-0460

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the United States Code (USC) and Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-139-0460
Drugs and Devices: Take-back Program
(1) A RDSP that operates a drug take-back collection program or that participates in a drug take-back program under ORS 459A.200 to ORS 459A.266 as an authorized collector must be registered with the DEA as an authorized collector to collect controlled and non-controlled drugs for destruction.¶
(2) A RDSP that operates as a Drug Enforcement Agency (DEA) authorized collector must notify the board within 30 days of initiating or terminating the program and must establish and enforce policies and procedures, including but not limited to:¶
(a) Provision of a secure location of the collection receptacle inside the retail drug outlet, which is accessible to the public, within view of the pharmacy counter and must not be located behind the pharmacy counter; and¶
(b) Provision of adequate security measures, including proper installation and maintenance of the collection receptacle, tracking of liners, documentation, and key accountability; and¶
(c) Personnel training and accountability.¶
(3) A RDSP must inform consumers to directly deposit drugs into the collection receptacle. Pharmacy personnel must not count, sort, inventory, or otherwise handle drugs collected.¶
(4) A RDSP must not dispose of drugs from pharmacy stock in a collection receptacle.¶
(5) The liner must be inserted and removed from a locked collection receptacle only by or under the supervision of two employees of the pharmacy. Upon removal, the liner must be immediately sealed, and the pharmacy employees must document their participation in the insertion and removal of each liner from a collection receptacle on a log. Sealed liners must not be opened, analyzed, or penetrated at any time by the pharmacy or pharmacy personnel.¶
(6) Liners that have been removed from a collection receptacle and immediately sealed must be directly transferred, or otherwise stored in a secured, locked location in the pharmacy for no longer than 14 days prior to being transferred, by two pharmacy personnel to a registered drug distribution agent (such as registered UPS, FedEx, or USPS) or a reverse wholesaler registered with the DEA and the board.¶
(7) Any tampering with a collection receptacle, liner or theft of deposited drugs must be reported to the board in writing within one day of discovery.¶
(8) A RDSP must maintain all drug disposal records for a minimum of 3 years.¶
(9) Authorized collectors are required to comply with the following federal and state laws:¶
(a) ORS 459A.200, ORS 459A.203, ORS 459A.206, ORS 459A.209, ORS 459A.212, ORS 459A.215, ORS 459A.218, ORS 459A.221, ORS 459A.224, ORS 459A.227, ORS 459A.230, ORS 459A.233, ORS 459A.236, ORS 459A.239, ORS 459A.242, ORS 459A.245, ORS 459A.248, ORS 459A.251, ORS 459A.254, ORS 459A.257, ORS 459A.260, ORS 459A.263, and ORS 459A.266;¶
(b) OAR 340-098-0000, OAR 340-098-0010, OAR 340-098-0300, OAR 340-098-0350, OAR 340-098-0370, and OAR 340-098-0390;¶
(c) 21 CFR 1317.30 (v. 04/01/2024~~4~~5), 21 CFR 1317.35 (v. 04/01/2024~~4~~5), 21 CFR 1317.40 (v. 04/01/2024~~4~~5), 21 CFR 1317.55 (v. 04/01/2024~~4~~5), 21 CFR 1317.60 (v. 04/01/2024~~4~~5), 21 CFR 1317.65 (v. 04/01/2024~~4~~5), 21 CFR 1317.70 (v. 04/01/2024~~4~~5), 21 CFR 1317.75 (v. 04/01/2024~~4~~5), 21 CFR 1317.80 (v. 04/01/2024~~4~~5), and 21 CFR 1317.85 (v. 04/01/2024~~4~~5); and¶
(d) 21 USC 822 (v. 0~~3~~2/2~~5~~6/2025~~5~~6) and 21 USC 822a (v. 0~~3~~2/2~~5~~6/2025~~5~~6).¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205, ORS 459A.266
Statutes/Other Implemented: ORS 689.305, ORS 459A.203, ORS 459A.215, ORS 495A.218

AMEND: 855-141-0350

NOTICE FILED DATE: 04/15/2026

RULE SUMMARY: Rule amendments are required per ORS 183.337 and pursuant to ORS 475.035 and ORS 475.055. Revises referenced versions of the Code of Federal Regulations (CFR).

CHANGES TO RULE:

855-141-0350
Dispensing: Containers
Each PPK must dispense a drug in a new container that complies with the current provisions of the Poison Prevention Packaging Act in 16 CFR 1700 (v. 01/01/2024~~4~~5), 16 CFR 1701 (v. 01/01/2024~~4~~5), and 16 CFR 1702 (v. 01/01/2024~~4~~5). ¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 689.155